Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 10 drugs with upcoming expirations
Pipeline
By Phase
1 drugs in development
By Therapeutic Area
top 1
R&D Momentum
30/100
Pipeline Velocity
11/100
Trial Completion Rate
N/A
Pipeline Concentration
100/100
Pipeline Freshness
95/100
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Regulatory
Nimotop — NYMALIZE
Application NDA203340 (NDA)
CeeNU — GLEOSTINE
Application NDA017588 (NDA)
Treanda — BENDEKA
Application NDA208194 (NDA)
Adzenys Er — ADZENYS XR-ODT
Application NDA204326 (NDA)
Adzenys Er — ADZENYS ER
Application NDA204325 (NDA)
Rilutek — TIGLUTIK KIT
Application NDA209080 (NDA)
Treanda — BELRAPZO
Application NDA205580 (NDA)
Tasigna — TASIGNA
Application NDA022068 (NDA)
Rilutek — EXSERVAN
Application NDA212640 (NDA)
Adzenys Er — EVEKEO ODT
Application NDA209905 (NDA)
Treanda — BENDAMUSTINE HYDROCHLORIDE
Application NDA211530 (NDA)
Treanda — BENDAMUSTINE HYDROCHLORIDE
Application NDA216078 (NDA)
Treanda — VIVIMUSTA
Application NDA212209 (NDA)
Treanda — BENDAMUSTINE HYDROCHLORIDE
Application NDA215033 (NDA)
Zonegran — ZONISADE
Application NDA214273 (NDA)
Depo-Testosterone — AZMIRO
Application NDA216318 (NDA)
Tasigna — DANZITEN
Application NDA219293 (NDA)
Feraheme — FERABRIGHT
Application NDA219868 (NDA)
Treanda — BENDAMUSTINE HYDROCHLORIDE
Application NDA219014 (NDA)
Tasigna — CAVHANZA
Application NDA217379 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)